Impact of systemic resveratrol on non-surgical periodontal treatment of smokers: A 12-month randomized clinical trial.
- 2025-08-30
- RCT · n = 19
- Clinical oral investigations 29(9)
- Vanessa Haguihara Lucchesi
- Ana Paula Oliveira Giorgetti
- Mônica Grazieli Corrêa
- Vanessa G A Pecorari
- Bruno Braga Benatti
- Howard C Tenenbaum
- Fabiano Ribeiro Cirano
- Suzana Peres Pimentel
- Márcio Zafallon Casati
- PubMed: 40884630
- DOI: 10.1007/s00784-025-06517-9
- High evidence
- Clinical
The concentration of Aggregatibacter actinomycetemcomitans (Aa) was significantly higher in moderate [2.29 (1.10); 1.61 (1.02) for PL and RSV, respectively] and deep PD [2.39 (1.14); 1.73 (0.90) for PL and RSV respectively] at 3 months for the Placebo group (p < 0.05). Additionally, Aa levels were lower at 6 months in the deep sites for the RSV group (p < 0.05) [1.77 (0.94); 2.23 (1.08) for PL and RSV, respectively].
- Effect
- Beneficial
- Effect size
- Small
- Significant
- Yes
- Dose
- 500 mg/day